Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data

被引:14
作者
Srinivas, Nuggehally R. [1 ]
机构
[1] Suramus Bio, Bangalore 560078, Karnataka, India
关键词
cyclosporine; pharmacokinetics; peak concentration; TDM; exposure; AUC; limited sampling strategy; transplant; renal; MICROEMULSION CYCLOSPORINE; GRAPEFRUIT JUICE; PHARMACOKINETIC INTERACTION; ADMINISTERED CYCLOSPORINE; TRANSPLANT PATIENTS; A PHARMACOKINETICS; PEDIATRIC-PATIENTS; MYCOPHENOLIC-ACID; AFRICAN-AMERICAN; TACROLIMUS;
D O I
10.1002/bdd.1967
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is an ongoing debate on the use of a single concentration time point C2 for therapeutic drug monitoring (TDM) and exposure prediction for cyclosporine. The objective of the present work was to evaluate the relationship between the peak concentration (C-max) versus area under the curve (AUC) for cyclosporine. Using published data from renal transplant patients from an 8-12 week study with two formulations, a simple linear regression model represented by AUC - cyclosporine = Cmax - Cyclosporine x 3.9965 + 384.5 (r = 0.9647; p < 0.001) was developed. Using the regression equation, predictions of AUC from the reported C-max data were performed; the fold difference between observed vs predicted AUC was computed and the root mean square error for the prediction was calculated. While all but one of the predicted AUCs were contained within a 0.5-2-fold difference (99.1%), a greater proportion of the AUC values were predicted within a narrower range of 0.75 to 1.5-fold difference (78.2%), suggesting the utility of C-max as the right surrogate for predicting the AUC for cyclosporine with a correlation coefficient of 0.8698 (n = 126; p < 0.001) and a RMSE of 26.2%. Since the time to C-max generally varies from 1 to 2 h, although the results validate the use of C2, there may be an opportunity to explore the suitability of C1 or C1.5 in a prospective study for the purpose of TDM and AUC prediction of cyclosporine. Copyright (C) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:575 / 586
页数:12
相关论文
共 55 条
[1]   Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients [J].
Åsberg, A ;
Hartmann, A ;
Fjeldså, E ;
Bergan, S ;
Holdaas, H .
AMERICAN JOURNAL OF TRANSPLANTATION, 2001, 1 (04) :382-386
[2]   PHARMACOKINETICS OF ORALLY AND INTRAVENOUSLY ADMINISTERED CYCLOSPORINE IN PRE-KIDNEY TRANSPLANT PATIENTS [J].
AWEEKA, FT ;
TOMLANOVICH, SJ ;
PRUEKSARITANONT, T ;
GUPTA, SK ;
BENET, LZ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (01) :60-67
[3]   Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients [J].
Bauer, S ;
Störmer, E ;
Johne, A ;
Krüger, H ;
Budde, K ;
Neumayer, HH ;
Roots, I ;
Mai, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :203-211
[4]   The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors [J].
Benjamin, B. ;
Sahu, M. ;
Bhatnagar, U. ;
Abhyankar, D. ;
Srinivas, N. R. .
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (04) :194-201
[5]   Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients [J].
Bergman, AJ ;
Burke, J ;
Larson, P ;
Johnson-Levonas, AO ;
Reyderman, L ;
Statkevich, P ;
Maxwell, SE ;
Kosoglou, T ;
Murphy, G ;
Gottesdiener, K ;
Robson, R ;
Paolini, JF .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (03) :328-336
[6]   Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects [J].
Bergman, AJ ;
Burke, J ;
Larson, P ;
Johnson-Levonas, AO ;
Reyderman, L ;
Statkevich, P ;
Kosoglou, T ;
Greenberg, HE ;
Kraft, WK ;
Frick, G ;
Murphy, G ;
Gottesdiener, K ;
Paolini, JF .
JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (03) :321-327
[7]   Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients [J].
Bleck, JS ;
Thiesemann, C ;
Kliem, V ;
Christians, U ;
Hecker, H ;
Repp, H ;
Frei, U ;
WesthoffBleck, M ;
Manns, M ;
Sewing, KF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (06) :551-556
[8]   Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients [J].
Budde, K ;
Lehne, G ;
Winkler, M ;
Renders, L ;
Lison, A ;
Fritsche, L ;
Soulillou, JP ;
Fauchald, P ;
Neumayer, HH ;
Dantal, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07) :781-791
[9]  
Cantarovich M, 1998, CLIN TRANSPLANT, V12, P243
[10]   Hepatobiliary excretion and enterohepatic circulation of colchicine in rats [J].
Chen, Yu-Jen ;
Huang, Shiou-Mei ;
Liu, Chia-Yuan ;
Yeh, Pen-Ho ;
Tsai, Tung-Hu .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 350 (1-2) :230-239